Excepting CD5, this study has not addressed the underlying biological mechanisms that drive clinical behaviour in aggressive B‐cell lymphoma, and genetic investigations and cell‐of‐origin immunostainings were not conducted universally. This evidence concerns the gene CD5 and B-cell non-Hodgkin lymphoma.